Atossa Therapeutics Announces Year-End 2023 Financial Result

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

New York , United States , Australia , American , Australian , Matthew Goetz , Eric Van Zanten , Jonathan Finn , Tessa Cigler , Weill Cornell Breast Center , Exchange Commission , Australian Taxation Office , American Association For Cancer Research , Vantage Consulting Group , Mayo Clinic Comprehensive Cancer Center , Development Expense , Atossa Therapeutics Inc , Nasdaq , Mayo Clinic Women Cancer Program , Endoxifen Clinical Trial , Re Evaluating Conditions , Active Surveillance Suitability , Ductal Carcinoma In Situ , Oestrogen Receptor , Human Epidermal Growth Factor Receptor , Endoxifen Versus , American Association , Cancer Research , Mayo Clinic Women , Executive Vice President , Chief Investment Officer , Steven Quay , Chief Executive , Year Ended December , Expenses Total , Administrative Expense , Selective Estrogen Receptor Modulator , Atossa Therapeutics , Public Relations , Private Securities Litigation Reform Act , Nasdaq Stock Market , Annual Reports , Quarterly Reports ,